Patents Represented by Attorney, Agent or Law Firm Gary R. Fabian
  • Patent number: 5716780
    Abstract: The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 10, 1998
    Assignee: Genelabs Technologies, Inc.
    Inventors: Cynthia A. Edwards, Kirk E. Fry, Charles R. Cantor, Beth M. Andrews
  • Patent number: 5707830
    Abstract: The present invention describes an expression vector useful for transfection of a selected mammalian host cell. The vector includes the following components: an Epstein Barr Virus (EBV) family of repeats; a copy of the EBV Nuclear Antigen-1 (EBNA-1) gene that can be functionally expressed in the host cell; a eucaryotic DNA fragment, which provides the ability of the vector to replicate in host cells; and an expression cassette which comprises a promoter functional in said host cell, a coding sequence having 5' and 3' ends, where said coding sequence is functionally linked to said promoter, where said 5' end is adjacent the promoter and said 3' end is adjacent transcription termination sequences. The vector of the present invention is useful in the transfection of mammalian cells, including rodent and human cells. The vector is stably retained and replicates in concert with genomic sequences of the host cell, that is, the vector is typically replicated once per cell cycle.
    Type: Grant
    Filed: April 2, 1997
    Date of Patent: January 13, 1998
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventor: Michele Pamela Calos
  • Patent number: 5705363
    Abstract: The present invention describes the production of interferon-.tau. proteins and polypeptides derived therefrom. The antiviral and anticellular proliferation properties of these proteins and polypeptides are disclosed. One advantage of the proteins of the present invention is that they do not have cytotoxic side-effects when used to treat cells. Structure/function relationships for the interferon-.tau. protein are also described. In one aspect, the invention includes ovine interferon-.tau.. In another aspect the invention includes multiple forms of human interferon-.tau..
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: January 6, 1998
    Assignee: The Women's Research Institute
    Inventor: Kazuhiko Imakawa
  • Patent number: 5700642
    Abstract: The present invention provides modified oligonucleotide primers that (i) are designed for attachment to a solid support in a manner that does not block the ability to extend the primer from its 3' end, and (ii) incorporate a clearable moiety so that a 3' portion of the primer (linked to an extension product) can be released from an immobilized 5' portion. Upon selective cleavage of the cleavable site, a large portion of the primer fragment remains affixed to the solid support. This enables the release of primer extension products that contain about five or fewer base pairs of the primer sequence, to provide more useful sizing and sequence information per fragment than extension products containing the entire primer.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: December 23, 1997
    Assignee: SRI International
    Inventors: Joseph Albert Monforte, Christopher Hank Becker, Thomas Andrew Shaler, Daniel Joseph Pollart
  • Patent number: 5693506
    Abstract: This invention provides for the secretion of heterologous protein in plant systems. In particular, this invention provides for the production of heterologous proteins in plant cultu1res and seeds. Where seeds are the source of the protein, the heterologous genes are expressed during germination and isolated from a malt.
    Type: Grant
    Filed: November 16, 1993
    Date of Patent: December 2, 1997
    Assignee: The Regents of the University of California
    Inventor: Raymond L. Rodriguez
  • Patent number: 5693463
    Abstract: The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.
    Type: Grant
    Filed: December 23, 1992
    Date of Patent: December 2, 1997
    Assignee: Genelabs Technologies, Inc.
    Inventors: Cynthia A. Edwards, Kirk E. Fry, Charles R. Cantor, Beth M. Andrews
  • Patent number: 5675061
    Abstract: The present invention describes vectors and methods useful for the production of transgenic mollusks, in particular, transgenic abalone. The invention further describes transgenic mollusks having enhanced growth properties. In addition, the isolation and characterization of an abalone actin gene promoter region is disclosed.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: October 7, 1997
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Dennis Alpha Powers, Lynna Madsen Hereford, deceased, Marta Gomez-Chiarri
  • Patent number: 5670316
    Abstract: The present invention describes the formation of RecA protein catalyzed double-stranded probe:duplex linear target DNA complexes that are stable to deproteinization. The uses of this stable probe:target complex in diagnostic/DNA detection systems in in vitro and in situ DNA hybridization reactions is discussed. The probe:target complexes are also useful for diagnostic application in RecA protein facilitated DNA amplification reactions.
    Type: Grant
    Filed: May 25, 1994
    Date of Patent: September 23, 1997
    Assignee: Daikin Industries, Ltd.
    Inventors: Elissa P. Sena, Cornelia J. Calhoun, David A. Zarling
  • Patent number: 5643718
    Abstract: A method of transient transfection of obligate intracellular parasites is described. This method is exploited to develop a system for stable transformation utilizing selectable genes. For example, introduction of the chloramphenicol acetyl transferase (CAT) gene fused to Toxoplasma flanking sequences followed by chloramphenicol selection results in parasites stably expressing CAT. DNA hybridization analysis indicated that the CAT gene had inserted via homologous recombination.
    Type: Grant
    Filed: November 4, 1993
    Date of Patent: July 1, 1997
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kami Kim, Dominique Soldati, John C. Boothroyd
  • Patent number: 5643714
    Abstract: Novel HTLV-I and HTLV-II peptides are disclosed for use in diagnostic assays for detecting and confirming HTLV-I and HTLV-II infection in human sera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp21 envelope protein, and are diagnostic of HTLV-I or HTLV-II infection. The invention also includes an assay kit and method for detecting, and discriminating between, HTLV-I and HTLV-II infection in humans.
    Type: Grant
    Filed: February 5, 1993
    Date of Patent: July 1, 1997
    Assignees: Genelabs Technologies, Inc., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kenneth G. Hadlock, Chin-Joo Goh, Steven K.H. Foung
  • Patent number: 5614366
    Abstract: Novel HTLV-I and HTLV-II peptide antigens are disclosed for use in diagnostics assays for screening and confirming HTLV-I and HTLV-II antisera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp46 envelope proteins, and are differentiated by their immunoreactivity with an HTLV-II specific monoclonal antibody and by HTLV-I and HTLV-II antisera. The peptides are also useful in vaccine compositions.
    Type: Grant
    Filed: February 8, 1991
    Date of Patent: March 25, 1997
    Assignee: Genelabs Technologies, Inc.
    Inventors: Gregory R. Reyes, Kenneth G. Hadlock
  • Patent number: 5589623
    Abstract: A method for control of ethylene biosynthesis in plants comprising a vector containing a selective gene under plant promoter control, and a DNA insert comprising codons for a functional heterologous polypeptide having AdoMetase activity and flanked by a plant promoter on one side and a polyA signal sequence on the other side; and, transforming a plant host with said vector wherein the plant host transformed thereby is capable of expressing the heterologous polypeptide having AdoMetase activity under the control of said control region. The presence of the AdoMetase gene and the expression of AdoMetase in transgenic plants lowers AdoMet levels and generates an inhibitor of ACC synthase causing a corresponding decrease in ethylene biosynthesis and precursor availability.
    Type: Grant
    Filed: December 20, 1994
    Date of Patent: December 31, 1996
    Assignee: Agritope, Inc.
    Inventors: Adolph J. Ferro, Richard K. Bestwick, Lyle R. Brown
  • Patent number: 5578444
    Abstract: The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.
    Type: Grant
    Filed: December 20, 1993
    Date of Patent: November 26, 1996
    Assignee: Genelabs Technologies, Inc.
    Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin, Kirk E. Fry
  • Patent number: 5547748
    Abstract: Encapsulation of metals inside multilayered polyhedral shells of carbon (nanoencapsulates) is described. Many materials, such as metals and metal-carbides, can be encapsulated by the method of present invention, including metals such as lanthanides, transition metals, actinides and alloys. Some of these nanoencapsulate materials exhibit ferromagnetic and paramagnetic properties and have uses in the biomedical field as well as in recording media and composite materials.
    Type: Grant
    Filed: January 14, 1994
    Date of Patent: August 20, 1996
    Assignee: SRI International
    Inventors: Rodney S. Ruoff, Donald C. Lorents, Ripudaman Malhotra, Mark J. Dyer
  • Patent number: 5538865
    Abstract: Peptide antigens which are immunoreactive with sera from individuals infected with hepatitis C virus (HCV) are disclosed. Several of the antigens are immunologically reactive with antibodies present in individuals identified as having chronic and acute HCV infection. The antigens are useful in diagnostic methods for detecting HCV infection in humans. Also disclosed are corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic peptides.
    Type: Grant
    Filed: January 19, 1994
    Date of Patent: July 23, 1996
    Assignee: Genelabs Technologies, Inc.
    Inventors: Gregory Reyes, Jungsuh P. Kim, Randolph Moeckli
  • Patent number: 5521063
    Abstract: The present invention describes an assay system wherein target polynucleotide molecules are captured on a support by base-specific binding to support-bound polymers, which are themselves substantially uncharged, and the target polynucleotides can be detected on the basis of their backbone charge. The assay system may also include polycationic reporter molecules which are designed to bind to the fully charged analyte backbone, but not the uncharged (or substantially uncharged) polymer backbone. In one embodiment, the reporter molecules are composed of a polycationic moiety or tail designed to bind electrostatically to a fully charged polynucleotide, under conditions where the reporter does not bind to the less charged or uncharged binding polymer carried on the diagnostic reagent.
    Type: Grant
    Filed: February 9, 1993
    Date of Patent: May 28, 1996
    Assignee: Antivirals Inc.
    Inventors: James E. Summerton, Dwight D. Weller
  • Patent number: 5521083
    Abstract: A large granular lymphocyte (LGL) leukemia related virus has been isolated and characterized from patients having LGL leukemia. The virus appears to be related to the family of retroviruses including HTLV-I, HTLV-I and Bovine Leukemia Virus. Nucleic acid sequences of the virus are presented.
    Type: Grant
    Filed: May 13, 1994
    Date of Patent: May 28, 1996
    Assignee: The Research Foundation of State University of New York et al.
    Inventors: Thomas P. Loughran, Jr., Bernard J. Poiesz, Francis W. Ruscetti
  • Patent number: 5506098
    Abstract: A method of identifying the presence of a known target sequence in double-stranded DNA contained in a fixed cellular or subcellular biological structure. By adding a stable, reporter-labeled RecA/single-stranded probe complex to the structure, the target sequence can be effectively labeled by in situ hybridization, allowing the target sequence to be visualized histologically and microscopically or detected by in situ cytometry or cell sorting flow techniques.
    Type: Grant
    Filed: September 4, 1991
    Date of Patent: April 9, 1996
    Assignee: Daikin Industries, Ltd.
    Inventors: David A. Zarling, Cornelia J. Calhoun, Elissa P. Sena
  • Patent number: 5470974
    Abstract: A composition of polymer molecules effective to bind, with substantially uniform binding affinity, to a single-stranded polynucleotide containing a target sequence of bases. The polymer molecules are composed of a sequence of base-pairing moieties effective to hydrogen bond to corresponding, complementary bases in the target sequence, under selected binding conditions, and a predominantly uncharged, achiral backbone supporting the base-pairing moieties at positions and in orientations which allow hydrogen bonding between the pairing moieties of the polymer and the corresponding complementary bases in the target sequence. The composition has diagnostic uses, in a solid-support assay system, and therapeutic uses involving inhibition or inactivation of target polynucleotides.
    Type: Grant
    Filed: February 25, 1994
    Date of Patent: November 28, 1995
    Assignee: Neu-Gene Development Group
    Inventors: James Summerton, Dwight Weller, Eugene Stirchak
  • Patent number: 5443965
    Abstract: Peptide antigens which are immunoreactive with sera from individuals infected with hepatitis C virus (HCV) are disclosed. Several of the antigens are immunologically reactive with antibodies present in individuals identified as having chronic and acute HCV infection. The antigens are useful in diagnostic methods for detecting HCV infection in humans. Also disclosed are corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic peptides.
    Type: Grant
    Filed: April 5, 1991
    Date of Patent: August 22, 1995
    Assignee: Genelabs Incorporated
    Inventors: Gregory R. Reyes, Jungsuh P. Kim, Randolph Moeckli